Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)

Dr. Jorge G. Darcourt

Hematology Oncology | Oncology | Hematology
Texas Oncology PA
1350 1st Colony Blvd, 
Sugar Land, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Texas Oncology PA
1350 1st Colony Blvd, 
Sugar Land, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jorge Darcourt is a Hematologist Oncology specialist and an Oncologist in Sugar Land, Texas. Dr. Darcourt is rated as an Experienced provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Breast Cancer, Thymic Epithelial Tumor, Paget Disease of the Breast, and Prostate Cancer. Dr. Darcourt is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Houston Methodist Hospital
Memorial Hermann Hospital System
Memorial Hermann Sugar Land Hospital
Houston Methodist Sugarland Hospital
Languages Spoken
English
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

TEXAS ONCOLOGY PA
1350 1st Colony Blvd, Sugar Land, TX 77479

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase Ib Trial of L-NMMA in Combination with Pembrolizumab in Patients with Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors
Phase Ib Trial of L-NMMA in Combination with Pembrolizumab in Patients with Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Primary Mediastinal Large B-cell Lymphoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Microsatellite Instability-High/Mismatch Repair Deficient Cancer, or for the Treatment of Adult Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: NG-Monomethyl-L-Arginine, Pembrolizumab
Study Phase: Phase 1
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Hydroxytyrosol
Study Phase: Phase 2/Phase 3
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

11 Total Publications

Erratum: Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic.
Erratum: Analysis of the Implementation of Telehealth Visits for Care of Patients With Cancer in Houston During the COVID-19 Pandemic.
Journal: JCO oncology practice
Published: March 19, 2025
Similar Doctors
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert Z. Orlowski
Hematology Oncology | Oncology
Distinguished in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Robert Z. Orlowski
Hematology Oncology | Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (15.5 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski is rated as an Elite provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Celyne L. Bueno-Hume
Hematology Oncology | Hematology | Oncology
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Celyne L. Bueno-Hume
Hematology Oncology | Hematology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (16.1 miles away)
713-794-5446
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Celyne Bueno-Hume is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Bueno-Hume is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Oral Squamous Cell Carcinoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Bueno-Hume is currently accepting new patients.

Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Martha P. Mims
Hematology Oncology | Hematology | Oncology
Advanced in Monoclonal Gammopathy of Undetermined Significance (MGUS)
Dr. Martha P. Mims
Hematology Oncology | Hematology | Oncology

Baylor College Of Medicine

6720 Bertner Ave, 
Houston, TX 
 (15.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Martha Mims is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Mims is rated as a Distinguished provider by MediFind in the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS). Her top areas of expertise are Hypereosinophilic Syndrome, Essential Thrombocythemia, Non-Hodgkin Lymphoma, and Clear Cell Sarcoma. Dr. Mims is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Darcourt's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 82 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile